Innovent Biologics’ CT103A, a promising therapy for tough-to-treat blood cancer, has shown positive results in clinical trials.
Takeda has announced clinical study results combining oral investigational MLN9708 with lenalidomide and dexamethasone, in patients with newly diagnosed multiple myeloma.
Takeda has initiated enrollment of patients in Japan in an ongoing global Phase III clinical study of its novel oral proteasome inhibitor MLN9708.
Researchers have identified a molecule that may be a potential biomarker for multiple myeloma.
Aeterna Zentaris' partner, Yakult Honsha, has initiated a Phase I/II trial in Japan assessing the use of perifosine in combination with capecitabine for the treatment of colorectal cancer.
The Forgotten Cancers Project launched yesterday by the Cancer Council Victoria hopes to understand the causes of less common and under-researched cancers.